Identification of death receptors DR4 and DR5 in HTB-12 astrocytoma cell lines and determination of TRAIL sensitivity

Abstract

Astrocytomas are tumors which arise from astrocytes, cells that form the blood-brain barrier. There are very few drugs that successfully treat brain tumors. In this study, the cytotoxic effects on the HTB-12 astrocytoma cell line by tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) were studied. The presence of the TRAIL receptors, Death receptor 4 (DR4) and Death receptor 5 (DR5), were detected in HTB-12 cells by Enzyme-Linked Immunosorbent Assay (ELISA). Cytotoxicity assay by Trypan Blue Exclusion Method showed effective cell killing by TRAIL treatment. Thus, the presence of death receptors and TRAIL efficacy raises the therapeutic potential for this type of brain tumor.

TRAIL Suppresses Human Breast Cancer Cell Migration via MADD/CXCR7

“…TRAIL, an Apo2 ligand, is a member of the cytokine tumor necrosis factor (TNF) superfamily, which induces apoptosis in a wide variety of tumors without harming normal cells (Riddick et al, 2013). So, TRAIL-based therapy is currently evaluated in clinical studies.…”

Chaperonin‐containing tailless complex polypeptide 1 subunit 6A correlates with increased World Health Organization grade, less isocitrate dehydrogenase mutation, and deteriorative survival of astrocytoma patients

“…Astrocytoma, one of the most common and aggressive type of primary brain tumors in adults, is a fatal malignant tumor with natural resistance to many drugs due to the inability of anti‐tumor drugs in crossing the blood‐brain barrier 1,2 . Although resection with or without following radiotherapy and chemotherapy remains the leading treatment modality in general astrocytoma patients, the prognosis of astrocytoma patients is diverse according to classification issued by the World Health Organization (WHO), of which, astrocytoma patients with low grade (WHO grade I‐II) have a better survival outcome with a 5‐year survival of 63.8%–65%, 3‐5 while high‐grade (WHO grade III‐IV) astrocytoma patients are accompanied with a worse clinical outcome with a 5‐year survival rate of less than 5% 6 .…”

“…Astrocytoma, one of the most common and aggressive type of primary brain tumors in adults, is a fatal malignant tumor with natural resistance to many drugs due to the inability of anti-tumor drugs in crossing the blood-brain barrier. 1,2 Although resection with or without following radiotherapy and chemotherapy remains the leading treatment modality in general astrocytoma patients, the prognosis of astrocytoma patients is diverse according to classification issued by the World Health Organization (WHO), of which, astrocytoma patients with low grade (WHO grade I-II) have a better survival outcome with a 5-year survival of 63.8%-65%, [3][4][5] while high-grade (WHO grade III-IV) astrocytoma patients are accompanied with a worse clinical outcome with a 5-year survival rate of less than 5%. 6 Even though great efforts have been given in exploring the biomarkers for prognosis of astrocytoma patients such as isocitrate dehydrogenase (IDH) mutation and deletion of 1p/19q, etc., 7,8 the urgent needs of finding additional biomarkers for evaluating disease status, predicting prognosis of astrocytoma, and further realizing its individualized treatment are still not met.…”